FDA approves heart drug for black patients.
The Food and Drug Administration's approval in June 2005 of a heart failure drug aimed at black patients marks the first time that the agency has approved a drug for a specific racial group. When added to standard heart failure therapy, BiDil dramatically reduces death and hospitalization in blacks.
Meadows
Michelle
M
D000959:Antihypertensive Agents / Q000627:therapeutic use*; D044383:Black People; D004338:Drug Combinations; D006333:Heart Failure / Q000188:drug therapy* / Q000208:ethnology; D006801:Humans; D006830:Hydralazine / Q000627:therapeutic use*; D007548:Isosorbide Dinitrate / Q000627:therapeutic use*; D008875:Middle Aged; D014481:United States; D014486:United States Food and Drug Administration; D014665:Vasodilator Agents / Q000627:therapeutic use*; D001741:Black or African American
D000959:Antihypertensive Agents; D004338:Drug Combinations; D014665:Vasodilator Agents; C431665:isosorbide-hydralazine combination; D006830:Hydralazine; D007548:Isosorbide Dinitrate